{
  "id": 14175405,
  "title": "Syndax's lung disease ambitions for Niktimvo end with a Phase 2 failure",
  "url": "https://urgent.news/2026/10/13/syndaxs-lung-disease-ambitions-for-niktimvo-end-with-a-phase-2-failure",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-13T10:25:02.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/syndaxs-lung-disease-ambitions-for-niktimvo-end-with-a-phase-2-failure/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Syndax is ending development of Niktimvo in a rare lung disease called idiopathic pulmonary fibrosis (IPF) after the treatment flunked a mid-stage trial. The company was evaluating Niktimvo in a placebo-controlled Phase 2 study. The ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}